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A B S T R A C T
Background: The effects of physical exercise in patients with lacunar stroke, seem promising in secondary pre-
vention and only few studies have investigated the effect of high-intensity interval training in patients with
lacunar stroke. This study will be investigating whether high-intensity interval training improves cardiovascular
fitness as well as cognitive- and endothelial function and potentially attenuating the risk of recurrent stroke.
Methods: A randomized controlled trial evaluating 12 weeks of home-based, high-intensity interval training
compared with usual care. The intervention group will be exercising 15min a day, 5 days a week, for 12 weeks.
Outcomes will be evaluated at baseline, three, six and twelve months post-stroke with ‘The Graded Cycling Test
with Talk Test’ as the primary outcome registered as power output in Watts. Additionally, an annually register-
based follow-up will be performed for 5 years from date of inclusion with a composite endpoint of cardiovascular
disease or death. Secondary outcomes will be: physical activity, endothelial response, mental well-being, cog-
nition, mood, fatigue, stress, and MRI scan.
Discussion: This study is going to show if early initiated home-based high-intensity interval training is feasible
and effective in patients with lacunar stroke. A self-chosen aerobic exercise modality allows a realistic im-
plementation of practice, together with greater chance of long-term adherence. A limitation of the study is that
recruitment bias cannot be ruled out, as there may be a preferential enrolment of patients who are self-motivated
to engage in exercise.
1. Introduction
Lacunar stroke accounts for one in four of all ischemic strokes [1],
and it is associated with a three-fold increase in the risk of a new stroke
and a high risk of cognitive decline and dementia [2]. Similar to other
stroke subtypes, the risk of a recurrent stroke is increased by co-factors
such as diabetes [2], hypertension, smoking [3], and physical inactivity
[2]. Recurrent strokes are usually more debilitating, with worse prog-
nosis and outcome, and a higher rate of discharge to long-term care
facilities [4]. The current secondary prevention of recurrent stroke is
antithrombotic, anticoagulant, antihypertensive and cholesterol redu-
cing treatment in addition to non-pharmacological interventions and
lifestyle changes. As the risk of recurrent stroke is between 3.7 and
6.7% within 90 days from stroke [5,6], secondary prevention including
lifestyle modifications should be initiated promptly [7]. Physical ac-
tivity is an important lifestyle modification to many co-morbidities [8].
Physical activity with improved aerobic fitness reduces lipids, blood
pressure and weight, thus promoting improved cardiovascular health
[9,10] with reduced morbidity and mortality [11]. Regular physical
activity also helps minimize the cognitive deficits post stroke [12].
Studies on stroke survivors identifies sedentary behaviour after
stroke [13,14], with activity levels below that of people with chronic
diseases of musculoskeletal or cardiovascular origin [15]. The cause of
the reduced physical activity is not fully understood as many patients
with stroke are able to be more physical active but choose not to be
[16]. This may represent a knowledge gap on exercise
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recommendations, fear of exercise inducing stroke, or lack of support in
daily physical activities [17].
We hypothesize that implementing high-intensity interval training
at home (defined as vigorous-intensity physical activity performed at
≥6 Metabolic Equivalent of Task (MET) [18]) within the first three
weeks of a lacunar stroke will improve cardiovascular fitness, physical
activity, cognition, endothelial response, and quality of life. Previous
studies have shown that supervised high-intensity interval training in
patients with stroke are feasible and effective in the late post-stroke
phase [19]. Therefore, the aim of this study will be to compare aerobic
change across a 3-month period of home-based high-intensity interval
training compared with aerobic change in usual care. Furthermore, we
are going to investigate changes in risk profile for a recurrent stroke
with long-term follow-up on cardiovascular events.
2. Methods and analysis
The study will be a parallel, two-arm, randomized controlled trial.
In addition to usual care (preventive medication and advice on self-
managed life-style changes), the intervention group will be doing
home-based high-intensity interval training during the first three
months post stroke compared with only usual care. Eligible patients
with recent (0–21 days) onset of symptoms of a lacunar stroke will be
randomized to intervention or control group. Patients will be assessed
post-intervention, and at follow-up (6 and 12 months post stroke). (See
Fig. 1: work flowchart). Subsequently, the patients will be followed
annually for five years after stroke using patient records, national re-
gistries and questionnaires evaluating numbers of vascular events or
death. Furthermore, baseline data from this RCT will be constituting a
cross-sectional study on self-reported pre-stroke physical activity and
post-stroke health profile in patients with lacunar stroke.
2.1. Recruitment
All patients will be in-patients recruited consecutively from the
stroke unit at Herlev Gentofte University Hospital, Copenhagen from
January 1st, 2016 with a target of 100 included patients. Recruited
patients for inclusion will be first episode lacunar stroke or patients
with recurrent lacunar stroke with clinical symptoms and a corre-
sponding ischemic lesion verified on MRI scan.
2.2. Participants
Lacunar stroke is defined according to the Trial of Org 10172 in
Acute Stroke Treatment (TOAST-criteria) [20] where the patients have
one of the traditional clinical lacunar syndromes, with relevant brain
stem or subcortical hemispheric lesion verified on CT scan or MRI scan.
In the acute phase, the lesion has a diameter< 2 cm [21], no cerebral
cortical dysfunction, no potential cardiac source for embolism and in
case of arterial stenosis, occlusion should be<50%. During admission
patients will be routinely examined with chest x-ray, continuous elec-
trocardiogram (ECG-monitoring) for 48 h (for heart arrhythmias) and
carotid artery stenosis screening (ultrasound).
Inclusion criteria will be symptoms of an acute lacunar stroke, ei-
ther with corresponding acute lesion on MRI scan, or with a previous
lacunar stroke on MRI scan (amendment 1, June 2016), age > 18
years, able to speak and read Danish, and be able to give informed
consent. Exclusion criteria will be prior large artery stroke, symptoms
or co-morbidities in the musculoskeletal system preventing exercise on
a stationary bike, uncontrolled hypertension or diabetes, dyspnoea
caused by heart or pulmonary disease, atrial fibrillation, carotid artery
stenosis (occlusion > 50%), aphasia or cognitive dysfunction inter-
fering with the Talk Test.
2.3. Screening process and enrolment
Eligible patients will be identified by daily screening of medical
records and they will be provided with written and oral information
about the study. Informed consent will be obtained by the study co-
ordinator and includes consent to collect and store biological speci-
mens. After completion of the baseline assessment, the patients will be
assigned to either intervention or control group. Personal information
about the patients will be collected, maintained and stored to protect
confidentiality before, during and after the trial. Only the study co-
ordinator and physicians involved in the study will have access to the
final trial dataset.
2.4. Randomization/blinding
The patients will be randomized consecutively into two groups:
exercise intervention and usual care or usual care only, based on equal
allocation with randomly varying block size. A computer-generated
block-randomization (8 blocks of 10, mixed with 5 blocks of 4) will be
administrated by a research assistant not involved in the study, and
unaware of patient assignment. Outcome assessor, data analysts and,
study coordinator will be blinded to the randomization process. Sealed
opaque envelopes made by the research assistant will be stored and
administrated by other personnel not involved in the study.
2.5. Outcome assessments
All outcome measures, except MRI scan, will be obtained at baseline
(0–21 days post stroke), post-intervention, 6 and 12 months post stroke
and subsequently registry-based outcomes will be obtained yearly
(Table 1). The study will be reporting at the prespecified time-points
with the same primary outcome (Power output from the Graded Cycling
Test with Talk Test (GCT-TT)). The first reported time point (after
baseline) is the post-intervention assessment, i.e. after 3 months, where
we aim to investigate the acute effect of the intervention (home-based
high-intensity interval training).
The subsequent follow-up assessments at 6 months and at 12
months will be reported together after the 12 months assessment to
explore whether the intervention group has made sustainable lifestyle
changes and kept the achieved exercise level post-intervention assess-
ment. At the 12 months follow-up the explorative analysis on the MRI
outcome changes will be done.
The primary outcome, is the change in power output registered in
Watts (W) from the GCT-TT. It will be performed by assessors, not in-
volved in the study and not performed in immediate association with
the intervention. Prior to the study the assessors will be introduced,
trained and calibrated in performing the GCT-TT (3 tests in healthy
adults and 3 tests in patients with minor stroke) by the study co-
ordinator.
Data from the secondary outcomes will be collected by the study
coordinator with prior training in administering questionnaires and
assessment tools. Data containing personal information will be col-
lected, anonymized and stored to protect confidentiality. Data access
will be limited to the study coordinator and physician involved in the
study.
2.5.1. Primary outcome
The power output registered in Watts (W) from the GCT-TT will be
the primary outcome measure.
The Talk Test (TT) in itself is a simple and valid estimate to evaluate
submaximal exercise intensity [22–29] and it is responsive to measure
changes in aerobic capacity following blood donation and aerobic
training [25]. The Talk Test has previously been used in combination
with various incremental exercise test protocols on treadmill
[24,25,27–32] or a stationary bicycle [22,26,32]. We will use TT with
the GCT protocol, which is a frequently used protocol in Denmark,
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where the general population are accustomed to cycling. The GCT is
performed on a stationary bicycle (Monark 928E-G3, Vansbro, Sweden)
using a ramp protocol with a 15 Watt increase each minute [33]. During
the last 10–15 s of each minute, the patients recite a standardised text
passage, followed by the question: “are you able to speak comfor-
tably?“. The patients can answer “yes”, “unsure” or “no”, and the test
stops when the patient answers “no” (not able to speak comfortably).
This point, identifies the highest possible exercise intensity where the
patient can speak comfortably without feeling disturbed by increased
breathing. A detailed test-protocol has previously been described [34].
The GCT-TT can be performed independently of the ability to assess
the maximal heart rate (e.g. in case of atrial fibrillation or beta-
blocker). Furthermore, it is easy and time effective to use, and it does
not require expensive equipment. Also, the test is assessor-independent,
as it is the patient who identifies the intensity level where he/she
cannot speak comfortably. These qualities of the GCT-TT make it an
attractive outcome measure in various rehabilitation settings. The GCT-
TT has shown good reliability and minor measurement error in both
patients with ischemic heart disease [35] and in patients with lacunar
stroke [34]. The Standard Error of Measurement with 95% certainty
(SEM95) in patients with lacunar stroke is: 12.9 Watt. Thus, a change of
≥12.9W reflects a real change in power output beyond measurement
error in a group of patients with lacunar stroke. For an individual pa-
tient with lacunar stroke, the Smallest Real Difference (SRD) is 18.3
Watt, indicating that a change of two steps in the incremental test
protocol (30 Watt) represents a real clinical change.
2.5.2. Long-term follow-up (5 years)
Patients will be followed 5-years post-stroke using patient journal,
registers (The Danish National Patient Registry and The Danish Stroke
Registry) and questionnaires to evaluate number of incidence of cere-
brovascular events (recurrent stroke) or death.
2.5.2.1. Secondary outcomes. Choices of secondary outcomes are based
on an interest to monitor potential improvement in symptoms of stroke
and risk factors for recurrent stroke. We also considered whether the
questionnaire was validated in a stroke population and was available in
Danish, and the total time spend on each outcome.
2.5.2.2. Endothelial function. Endothelial dysfunction is a known risk
Fig. 1. HITPALS-trial, Work flowchart.
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factor for cardiovascular diseases [36], hypertension [37],
hypercholesterolemia [37], and stroke [38].
Endothelial function is measured by a non-invasive method de-
termining the Peripheral Arterial Tonometry (PAT) by EndoPAT2000
(Itamar Medical Ltd, Caesarea, Israel). The PAT is measured by plastic
probes that impart a uniform pressure to the distal two third of the
index finger. The endothelial function estimates the changes in Pulse
Wave Amplitude (PWA) and is registered as the Reactive Hyperemia
Index (RHI). RHI is the post-to pre-occlusion signal ratio in the occluded
arm compared to the same ratio in the control arm and corrected for
baseline vascular tone of the occluded arm. A detailed test procedure is
previously described [39]. A lower RHI-value is associated with im-
paired endothelial function [40]. A RHI-value> 1.67 is recommended
as cut-off for normal endothelial function (abnormal function
is≤ 1.67), recommended by the EndoPAT2000-user manual. Further-
more, arterial stiffness is estimated using the Augmentation Index (AI)
and based on computerized averaging and analysis of multiple pulse
waveforms registered during baseline measurement on the occluded
arm. AI register change in peak systolic pulse wave after baseline oc-
clusion (%). Also, the heart rate-corrected Augmentation Index (AI@
75) is measured at the heart rate of 75 beats per minute. A previous
study investigating validation of repeated measurement of endothelial
function in patients with acute stroke found good day-to-day reliability
[39].
To reduce potential day-to-day variability, the assessment will be
carried out in the morning and the patients will be asked to refrain from
consuming any food or beverages after midnight. Assessment will be
performed in an undisturbed, dark room with a room temperature of
21–24 °C. Before assessment the patient will relax in supine position for
25min to reach cardiovascular steady state.
2.5.2.3. Physical activity. Physical inactivity is one of the major risk
factors for stroke why it is relevant to explore [41]. Physical activity
will be measured using a self-reported questionnaire; Physical Activity
Scale version 2.1 (PAS2) [42] and objectively with accelerometers worn
by the patient for a week at baseline, post-intervention and at 6 and 12
months, respectively.
PAS2 measures physical activity as daily hours and minutes of sleep,
sitting, standing or walking, and heavy physical work, transportation to
and from work, as well as TV-watching or reading. In addition, PAS2
measures weekly hours and minutes of light-intensity physical activity,
moderate intensity activity, and vigorous-intensity activity [42]. Each
of these domains correspond to a specific level of MET-intensity (The
Metabolic Equivalent of Task) [43], where 1MET is the rate of energy
expenditure while sitting at rest and corresponds to an oxygen uptake of
3.5 ml/kg of body weight per minute. Moderate-intensity activity refers
to the physical activity performed at 3.0–5.9METs and vigorous-in-
tensity activity correspond to>6METs [18]. The total measurement of
METs allows for indirect estimation of total physical activity during 24-
h. The construct validity of the Physical Activity Scale has been vali-
dated in 342 Danish men and women aged 35–66 years [42].
2.5.2.4. Objective assessment of activity by accelerometer. Objective
assessment of physical activity will be measured with a water
resistant and wireless three-axis accelerometer, AX3 (Axivity, York,
UK), recording with a frequency of 25 Hz. It will be fixed with double
sided adhesive tape (VIP Tape, Skinlock International, Charleroi,
Belgium), and sealed with a water-resistant patch (Fixomull®
transparent, BSN medical Inc, Hamburg, Germany) anteriorly on the
thigh. The position of the AX3 will be right medial thigh; midway
between the hip and knee joint, orientated with the x-axis pointing
downward, y-axis horizontally to the left, and z-axis horizontally
forward. The accelerometer will be initialized for recording and data
downloaded using manufacturer's software (Open Movement
v.1.0.0.28). Data from the accelerometer will be analysed using Acti4,
a custom made script in MATLAB (version R2013a) including a
previously described algorithm to identify everyday physical activity
types such as walking, running, cycling, climbing stairs, standing and
sitting [44]. Activity patterns will be recorded for 8 days and 7 nights,
including data from both weekdays and weekends. The AX3 is validated
in healthy subjects with a high specificity and sensitivity to differentiate
between the above-mentioned activities [44,45]. The monitor device
will be set during patient assessments at the hospital and returned by
mail using pre-paid envelopes. Furthermore, all patients will keep an
exercise diary reporting type, amount (in minutes) and intensity of
activity daily for 12 weeks.
2.5.2.5. Well-being. To evaluate well-being, we will be using the WHO-
5 Well-Being Index. It is a short, self-rated questionnaire evaluating
mental well-being [46]. It has adequate validity both as a screening tool
for depression and as an outcome measure in clinical studies [46]. The
WHO-5 Well-Being Index includes five positive statements on mental
well-being over the last two weeks, with respondent answers
distributed on a 6-point Likert-scale. The raw-score is calculated by
summation and ranges from 0 to 25 (the higher the score the better
mental well-being) and is often expressed as percentage of the maximal
Table 1
Outcome assessments.
Outcomes Abbreviation/device Function
Primary outcome
Power output in Watts from the Graded Cycling Test
with Talk Test
GCT with TT Submaximal aerobic exercise test
Secondary outcomes
Endothelial response EndoPAT2000 Endothelial function
Physical Activity Scale PAS2 Self-rated physical activity
Axivity AX3 Accelerometer monitoring physical activity
Mental well-being WHO-5 Well-Being Index Self-reported mental well-being
Montreal Cognitive Assessment MoCA Assessment of cognitive function
Major Depression Inventory MDI Self-reported depression symptoms
Multidimensional MFI-20 Self-reported fatigue symptoms
Fatigue Inventory
Chronic stress Ull-Meter Objective measurement of the body and mind’s state of stress
Vascular risk factors:
Blood pressure (resting) BP Systolic and diastolic blood pressure
Blood samples BS Measure of total cholesterol/ high-density lipoprotein ratio, cardiovascular biomarkers,
inflammatory biomarkers and endothelial biomarkers
Body Mass Index BMI Quantify the amount of tissue mass (muscle and fat)
MRI scan MRI Changes in brain structure after 12 months (regarding infarcts, white matter lesions, micro
bleeds)
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score [47]. To monitor changes in mental well-being, a relative
(percentage) score change of 10% is used to indicate significant
change [48]. The cut-off score indicating risk of depression or long-
term stress is set to 50 points [49] while the average score for the
Danish population is 69 points [47].
2.5.2.6. Cognition. The Montreal Cognitive Assessment (MoCA) is a
brief screening tool designed to identify mild cognitive impairments. It
assesses different cognitive domains: attention, concentration,
executive functions, memory, language, visuospatial ability,
conceptual thinking, calculations and orientation. The total score is
30 points and a score ≥26 is considered as normal [50]. The MoCA is
valid and reliable in patients with lacunar stroke and white matter
lesions [51].
2.5.2.7. Depression. The Major Depression Inventory (MDI) is a self-
reported questionnaire for diagnosing and assessing depression [52].
The questionnaire includes twelve questions on how the patient has
been feeling over the past two weeks. The response is given on a 6-point
Likert-scale, where 0 corresponds to: “At no time” and 5 corresponds to
“All the time”. The maximum score is 50 points and the higher score the
more severe the depression [52]. A score> 20 points indicates mild
depression, while a score> 15 points indicates incipient depression
[53].
2.5.2.8. Fatigue. Multidimensional Fatigue Inventory (MFI-20) is a 20-
item self-report instrument evaluating five dimensions of fatigue:
general fatigue, physical fatigue, mental fatigue, reduced motivation
and reduced activity [54]. Each dimension is covered by four questions
and the responder indicates on a 5-point Likert-scale, to what extent the
statement applies to him/her. Each dimension of fatigue is calculated
on a score from 4 to 20, with higher scores representing increased
fatigue [54,55]. We use the domain of general fatigue as a measure of
overall fatigue as proposed in the original development of the scale
[54].
2.5.2.9. Chronic stress. Chronic stress will be measured using an
algometer (Ull-Meter®), an objective instrument measuring the pain
threshold on the sternum, called pressure pain sensitivity (PPS)
[56,57]. The algometer is the size of a whiteboard marker and is easy
to use. The patient will be in a supine position, and for 5 s the Ull-Meter
will be gradually pushed against the area identified as the most
sensitive point of the sternum. When the patient experiences
discomfort, the pressure is stopped and the PPS is read on a scale
from 30 to 100, with a cut-off point ≥60, correlating with markers of a
stress syndrome [58]. The result is blinded from the observer until the
measurement has finished [56,57]. In both healthy people and patients
with chronic disease such as ischemic heart disease, PPS is associated
with several elements of the chronic stress syndrome: depression score,
quality of life scores, and numbers of stress reactions [56–58]. Stress
intervention studies aiming at reducing PPS have demonstrated
clinically relevant reduction in several risk factors for ischemic heart
disease and in healthy control subjects [59]. Furthermore, in a previous
study on patients with ischemic heart disease, stress-reducing treatment
aiming at reducing PPS demonstrated a concomitant decline in Major
Depression Inventory (MDI) and an increase in mental well-being
(WHO-5 Well-Being Index) [60].
2.6. Blood pressure
The blood pressure (systolic and diastolic pressure) will be mea-
sured following an overnight fast. With the patient in a supine position
and after 5min of rest, blood pressure will be measured with an auto-
matic blood pressure monitor (Microlife® BP A100/Microlife® BP A3L
Comfort, Widnau, Switzerland).
2.6.1. Blood samples
To evaluate possible endothelial dysfunction, inflammation and risk
of cardiovascular event we hypothesize changes in endothelial bio-
markers (Vascular endothelial growth factor (VEGF), vascular cell ad-
hesion molecule 1 (VCAM-1), intercellular Adhesion Molecule 1 (ICAM-
1), E-selectin), inflammatory biomarkers (Interleukin-6 (IL-6), tumour
necrosis factor (TNF), high sensitivity C-reactive protein (hsCRP); li-
poprotein(a) (LIPA)) and in cardiovascular biomarkers (pro-
Adrenomedullin, pro-atrial natriuretic peptide and Copeptin); glucose
metabolism. Furthermore, a battery of routine analyses will be per-
formed on the day of examination (See Table 2: list of routine blood
samples). The inflammatory biomarkers and endothelial biomarkers
will be analysed according to the manufacturer's instructions, using
commercially available kits from Mesoscale, Rockville, USA. (V-PLEX
Plus human: IL-6 kit, TNF kit, ICAM-1 kit, VCAM-1 kit, VEGF kit, and E-
selectin kit). The cardiovascular biomarkers will be analysed according
to the manufacturer's instructions using commercially available kits and
software from BRAHMS GmbH, Hennigsdorf, Germany. (KRYPTOR
compact PLUS human: Pro-ADM kit, Pro-ANP kit, and copeptin kit). All
blood samples will be collected during fasting state and stored at
−80 °C until analysis.
2.6.2. Body Mass Index
Information on body weight and Body Mass Index (BMI) will be
acquired with a body composition monitor (OMRON HBF-500-E; Kyoto,
Japan). The height will be measured in centimetres and entered in the
body composition monitor together with sex and age.
2.6.3. Magnetic resonance imaging
Magnetic resonance Imaging (MRI) will be obtained at baseline and
at 12 months post stroke at Herlev Gentofte University Hospital,
Department of Radiology. Data is blinded for patient participation and
stored in a secure departmental network system. The scanning protocol
will consist of an initial set of anatomical scans (T1W, T2W, inversion
recovery and FLAIR), that serve as basis for radiological assessment.
Furthermore, a diffusion tensor imaging (DTI) sequence is acquired
followed by an Arterial Spin Labelling sequence (ASL) to quantify tissue
perfusion, two 3D T1W sequences at different flip angles (FA 7 and FA
20) to estimate the T1 time of the tissue and finally, a high spatial
resolution dynamic contrast-enhanced sequence (DCE) will be used to
gauge blood-brain barrier permeability. For the DCE sequence a single
dose (0.2ml/kg) of gadolinium (DOTAREM, Guerbet, France) will be
Table 2
List of routine blood samples.
Category Name of blood sample Units
Hematology Hemoglobin
Leucocytes
Thrombocytes
mmol/L
×109/L
×109/L
Electrolytes P-Glucose
P-Creatinine
P-Potassium
P-Sodium
mmol/L
μmol/Lmmol/L
mmol/L
Proteins P-Albumin
P-Reactive Protein (CRP)
P-Reactive Protein (HSCRP)
g/L
mg/L
mg/L
Enzymes P-Creatine
P-Alanintransaminase (ALAT)
P-Aspartattransaminase (ASAT)
U/L
U/L
U/L
Hemostasis P-Coagulation factors (APTT)
P-Coagulation factors (INR)
S
S
Endocrinology Glucose (HbA1c)
P-Thyrotropin (TSH)
mmol/L
×10−3IU/L
Lipids P-Cholesterol
P-cholesterol (LDL)
P-cholesterol (HDL)
P-Triglyceride
mmol/L
mmol/L
mmol/L
mmol/L
P: plasma, U/L: units/litre, S: Seconds.
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injected at the rate of 3ml/s. All scans will be performed on a 3T
clinical system (Ingenia, Philips Healthcare, Best, The Netherlands)
using a 32 element headcoil. The total scanning time per patient is
50min at each time-point (See Table 3 for the order and type of MRI-
sequences).
2.6.4. Other data collection
The following data will be retrieved from the patient record or the
patient: co-morbidity, symptoms, medication, smoking- and drinking
habits, educational level and occupation.
3. Intervention
Physical activity is one of the modifiable risk factors for stroke [41]
and should be initiated early after stroke. Many patients with stroke are
not familiar with regular physical exercise hence the intervention must
be simple, motivating, not time-consuming, realistic and easy to per-
form during daily living routines. To describe the intervention, Con-
sensus on Exercise Reporting Template (CERT) has been used [61].
In addition to usual care, the intervention group will perform un-
supervised high-intensity interval training at home, 15min a day, five
days a week for twelve weeks. High-intensity interval training is per-
formed in short bouts of rather high, but not maximal-intensity cardi-
ovascular exercise alternating with short periods of low intensity ex-
ercise [62]. The 15min of high-intensity interval training corresponds
to the WHO global recommendations on physical activity for health.
WHO recommend at least 75min of aerobic physical activity at vig-
orous-intensity throughout a five-day week. The exercise modality will
be tailored under the condition that it is aerobic, and the intensity will
reach the level where the patient is not able to speak comfortably.
All patients will attend a motivational talk with the study co-
ordinator at baseline with the purpose to encourage lifestyle beha-
vioural changes. The patients will also be introduced to an exercise
catalogue, presenting various modes of aerobic exercise. The catalogue
will consist of: brisk walking/Nordic walking, stair stepping, knee
lifting, outdoor cycling/cycling on a stationary bike, and running – all
exercise modalities aim to elicit an increase in heart rate.
To ensure an easy accessible exercise modality, all patients will be
offered to borrow a stationary bicycle (Kilberry® Magnetic Bike JC-950,
Proteus Sports Inc, Linkou Township, Taiwan) to use at home. The bike
monitors: time (minutes), distance (kilometre), energy expenditure
(calories), Speed (kilometres per hour), resistance (level 1–9), heart rate
(pulse) and cadence (rounds per minute), all of which are used for
motivation purpose. Furthermore, all patients will be provided with a
pocket sized, laminated standardised text passage (cue card), which
they will use to find the exercise intensity.
Duration of intervals and mode of recovery vary between different
study-protocols [63] thus, we have chosen an easy, realistic and clinical
implementable exercise program. The aerobic exercise will be per-
formed in intervals. Two minutes of warm-up (at self-chosen level)
followed by 3min of high-intensity interval training at the intensity
where the patient cannot speak comfortably any longer (corresponding
to the answer “No” in the Talk Test). This will be followed by 2min of
moderate intensity, followed by 3min of high intensity and so forth for
15min, each session. The feasibility of each exercise modality on how
to achieve out-of-breath level (e.g. TT) was tested in four healthy in-
dividuals prior to study planning. Before patients start exercising the
study coordinator will visit the patients at home to introduce the ex-
ercise program, including an introduction to the Talk Test (how to
reach the right exercise intensity and how to progress the exercise
program). The Talk Test will determinate the starting level of the in-
tervention and the patients will progress the intensity of the exercise
modality (e.g. when using the bicycle by increasing the work load or the
cadence) as they improve throughout the exercise program. At every
session patients will be encouraged to reach an exercise-intensity level
where they can no longer speak comfortably. For further motivation
and control of completion of work-out, the patients will be contacted by
phone, text message or e-mail on a weekly basis to ensure compliance.
The weekly call(s) will also be an opportunity to identify equipment
malfunction or adverse events. Adverse events will be documented in
the case report form (CRF). All exercise sessions will be tracked by an
individual exercise diary to ensure adherence. Adherence to the study
in general is encouraged by highlighting the importance of both groups
in producing valid study results.
3.1. Control group
The control group will receive usual care, consisting of individually
adapted preventive medication and advice on lifestyle changes.
Furthermore, they will be asked to resume their usual level of physical
activity and to track their activity in an individual exercise diary,
documenting type-, time and intensity of exercise.
Table 3
Order and type of MRI-sequences.
Sequence order MRI-sequence Purpose MRI parameters
1
2
3
4
T1W 3D gradient seq. (GRE).
(sagittal – S)
Inversion recovery with 3D GRE
acquisition (S)
T2W spin echo (SE) seq. (axial – Ax)
T1W GRE (Ax)
First seq. merely for planning purposes TR/TE (ms) 25/1.68
Voxel (mm) 1×1×6
TR/TE 6.9/1.68
Voxel 1.1× 1.1× 1.1
TR/TE 3000/80
Voxel 0.5× 0.5× 4
TR/TE 288/4.6
Voxel 0.5× 0.5× 4
5 Fluid Attenuated Inversion
Recovery (FLAIR)
For delineation of white matter lesions, hyperintensities corresponding to
leukoaraiosis (Ax)
TR/TE 11000/2800
Voxel 0.5× 0.5× 4
6 Diffusion Tensor Imaging seq. (Ax) For 3D indication of neural bundles and DWI assistance in the radiological
assessment
TR/TE 11000/2800
Voxel 0.5× 0.5× 4 b=0,1000, 32 directs
7 Pseudo-continuous Arterial Spin
Labelling (PCASL) (Ax)
For the assessment of tissue perfusion (resting-state CBF) TR/TE 4040/17
Voxel 2.75× 2.75× 5
Label distance 90mm, post delay 1600ms
8
9
T1W 3D GRE with flip angle (FA) 7
(Ax)
T1W 3D GRE with FA 20 (Ax)
Used to give a rough estimate of the tissue T1 time, which is a parameter in
the perfusion model (Patlak) applied to the DCE data
TR/TE 25/1.88
Voxel 0.75× 0.75× 4
TR/TE 25/1.92
Voxel 0.75× 0.75× 4
10 DCE To gauge blood-brain barrier permeability.
A single dose (0.2ml/kg) of gadoterate meglumine is injected at the rate of
3 ml/s
TR/TE 25/2.2
Voxel 0.75× 0.75× 4
Dyn. scan time 55.7 s
No. of dyn. 24
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Both control- and intervention group will be offered a control visit
with a nurse at the preventive outpatient clinic (Herlev Gentofte
University Hospital) within 2 months from stroke onset. The purpose of
the visit is to evaluate blood pressure and cholesterol level and to en-
sure appropriate medication. Furthermore, the purpose is to provide
advice on lifestyle changes regarding; food, smoking and alcohol intake.
3.1.1. Adverse events/Discontinuing
Adverse events will be monitored and registered during the study.
Discontinuation will be considered if a patient is either unexpectedly
readmitted to the hospital or emergency department for a disease other
than stroke, or if they experience severe symptoms such as muscu-
loskeletal pain, fracture or cardiac symptoms of any kind.
4. Statistical analyses
4.1. Sample size and statistical analyses
A sample size calculation based on the primary outcome (Graded
Cycling Test with Talk Test) was conducted with a standard deviation
(SD) of 37 Watt and a meaningful difference of 23 Watt. 84 patients (42
in each group) are needed with a power of 80% and a two-tailed α of
0.05. With dropouts taken into account (15%), we will aim to include
100 patients in total.
Data, from patients with complete outcome data, will be analysed
according to the group to which they were randomized, independent of
patient compliance. All available data for each patient will be included
in the analysis, also if the patient does not have all observations.
Missing data will not be imputed. The estimated treatment effects will
be calculated by the constrained longitudinal data analysis (cLDA)
which will give unbiased result under missing at random. In case of one
patient is missing all observations post baseline, the patient will be
excluded in the analysis. An explorative analysis will be conducted to
test for interaction effects on the following parameters; sex, age, family
status, and education. The rationale for performing this analysis is that
no prior studies have explored the effect of these parameters on exercise
efficacy in lacunar stroke. A general linear mixed effect model with
baseline constrains will be used for both primary and secondary out-
comes using constrained longitudinal data analysis (cLDA) [64]. No
other independent variables will be included in the analysis. The effect-
size will be calculated as the visit/treatment interaction at the specified
visit and given as model estimates of mean difference with 95% Con-
fidence Interval (CI). Changes over time within each assessment day on
all relevant outcomes will be performed with linear mixed effect model
and patients who do not show up at the assessment visits will be
counted as missing at that specific assessment point.
The 5-year outcomes, survival and cerebrovascular events, will be
analysed using time-to-events method. The Kaplan-Meier method will
be used for descriptive survival statistics and drawing survival curves,
and the Cox proportional hazard model will be used for analysing
confounders of survival and cardiovascular events. The long-term
analysis will be explorative as we do not expect it to have adequate
power as the study as the study is not powered to detect differences on
long-term outcome between treatment groups. Data from all included
patients in the baseline assessment will be used, except from the pa-
tients lost to follow-up.
The analysis of the MRI scans will be performed with Statistical
Parametric Mapping (SPM) with a paired design.
Before analysis, all variables will be controlled for normal dis-
tribution, and transformed if needed. Non-parametric testing will be
used if data diverge from normal distribution after transformation. All
tests will be two-sided and p-values< 0.05 will be considered sig-
nificant. Data will be analysed using Microsoft Excel 2010 (Microsoft
Corporation, Redmond, WA, USA) and IBM SPSS Statistics 22 (Armonk,
NY, USA) or a similar software. Statistical planning is conducted in
cooperation with a biostatistician.
4.2. Ethics approval and consent to participate
The study has been approved by The Danish Data Protection Agency
(ID: HGH-2015-021) and adhere to the Danish low of data protection.
Furthermore, the study has been approved by the Research Ethics
Committee in the Capital Region of Denmark (H-15012371) according
to the Declaration of Helsinki of 1964, as revised in 2008. The study is
registered at ClinicalTrials.gov (NCT02731235, registered Jan. 2016)
and the reporting adheres to the SPIRIT 2013 statement [65]. All par-
ticipants will provide written informed consent before enrolment. Re-
sults of this study will be published in peer-reviewed international
journals and they will be presented at international and national con-
ferences.
Protocol H-15012371 (version 4.0, June 2016) amendment 1 has
been modified to allow an extended inclusion period from 0 to 21 days
(previously 0–7 days). In addition, inclusion of patients with recurrent
lacunar stroke, with clinical symptoms and a corresponding ischemic
lesion on MRI will be allowed. Amendment 2 (version 5.0, June 2017)
will be allowing inclusion from two other stroke units in the Capital
Region of Copenhagen due to low recruitment rate. The article de-
scribes protocol version 5.0 from June 6th. 2017.
5. Discussion
The aim of this study will be to report results on an early aerobic
exercise intervention carried out in the home environment of the pa-
tients. Firstly, this study will investigate whether it is possible to engage
patients in physical activity early after stroke. Secondly, it will in-
vestigate whether it is feasible and safe for patients with lacunar stroke
to do high-intensity interval training in their home environment and to
explore their adherence to exercise on a regular basis for twelve weeks.
Thirdly, we will monitor the long-term effects of the intervention on
cerebrovascular events and death (5 year).
If the intervention turns out to be feasible and effective, this study
will potentially contribute to establishing recommendations on exercise
programs and guidelines for patients with lacunar stroke. It will also be
interesting to explore whether there is a difference of having encoura-
ging phone calls on a weekly basis (intervention group) or the physical
assessments in itself at the post-intervention assessment (control group)
are sufficient. Furthermore, it will be interesting to explore, at six and
twelve-months follow-up, how many patients have kept doing exercise
on regular basis. This will provide us with information on how easy/
difficult it is to integrate physical activity as a routine in daily living
after lacunar stroke.
A strength of this study will be that patients can choose their pre-
ferred modality of aerobic exercise, as long as they exercise with an
intensity where they are unable to speak comfortably. With a self-
chosen exercise modality, the chances of long-term adherence will
potentially be higher. The home-based intervention will allow training
to occur at times which are suitable for the patient, just as it eliminates
limitations associated with transport to training facilities. As all patients
will be assessed post-intervention using GCT-TT on a stationary bicycle,
the free choice of exercise modality might be a potential bias. It has
been suggested that submaximal exercise thresholds such as ventilatory
threshold (VT) occur at a relatively lower exercise intensity during in-
cremental exercise tests using unfamiliar exercise modalities – i.e.
runners reach VT at a lower percentage of VO2max during cycling than
running [66]. Consequently, it could be expected that patients who
choose to exercise on stationary bicycles might perform better on the
GCT-TT compared with patients who choose to run.
To ensure a safe exercise intensity post stroke a continuous ECG-
recording for 48 h will be performed during hospitalization.
Furthermore, the patients will be completing their first aerobic exercise
test at the hospital in a safe environment together with an experienced
physiotherapist. Both actions should help making the patients feel safe
when exercising at home. Another strength is the relatively large
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sample size used which will allow the finding of the study to be gen-
eralized to other patients suffering from a lacunar stroke.
A limitation of the study will be the monitoring of physical activity
for one week only rather than the entire exercise period. Another lim-
itation is not being able to monitor the exercise intensity with heart rate
monitors. A smaller pilot study has shown that when recording heart
rate with ECG-electrodes for more than 3–5 days, the risk of developing
eczema on the chest was high, rendering poor quality data. The use of
commercially available heart rate monitors will be a challenge as the
study population are elderly with potential cognitive deficits. Secondly,
the current commercially available heart rate monitors have a limited
battery life and a limited memory capacity. Therefore, we anticipate
that the data quality will be too low if patients are unable to comply
with correct use of equipment that needs frequent recharging. Instead,
patients will record the amount of exercise in a diary. A possible bias
may be that only patients intended to engage in exercise will choose to
participate in the study. If this influences the activity of the control
group, it could diminish the difference in outcome measures between
the groups. This study will contribute information about the use of early
high-intensity interval training in patients with lacunar stroke.
Furthermore, we test the hypothesis that exercise can increase cardio-
vascular fitness and endothelial function and as a result, slow pro-
gression of vascular diseases and potentially prevent recurrent stroke.
Trial registration number
This study is registered at ClinicalTrials.gov (NCT02731235, regis-
tered January 2016).
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